Jacqui Miot1, Trudy Leong2, Simbarashe Takuva3,4, Andrew Parrish5, Halima Dawood6,7. 1. Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. jmiot@heroza.org. 2. National Department of Health, Affordable Medicines Directorate, Essential Drugs Programme, Pretoria, South Africa. 3. Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 4. School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. 5. Department of Internal Medicine, Cecilia Makiwane Hospital, East London, South Africa. 6. Department of Medicine, Greys Hospital, Pietermaritzburg, KwaZulu-Natal, South Africa. 7. Caprisa, University of KwaZulu-Natal, Durban, South Africa.
Abstract
BACKGROUND: Cryptococcal meningitis in HIV-infected patients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin B. Recent evidence has shown that the synergistic use of flucytosine improves efficacy and reduces toxicity, however affordability and availability has hampered access to flucytosine in many countries. This study investigated the evidence and cost implications of introducing flucytosine as induction therapy for cryptococcal meningitis in HIV-infected adults in South Africa. METHODS: A decision analytic cost-effectiveness and cost impact model was developed based on survival estimates from the ACTA trial and local costs for flucytosine as induction therapy in HIV-infected adults with cryptococcal meningitis in a public sector setting in South Africa. The model considered five treatment arms: (a) standard of care; 2-week course amphotericin B/fluconazole (2wk AmBd/Flu), (b) 2-week course amphotericin B/flucytosine (2wk AmBd/5FC), (c) short course; 1-week course amphotericin B/flucytosine (1wk AmBd/5FC) (d) oral course; 2-week oral fluconazole/flucytosine (oral) and e) 1-week course amphotericin B/fluconazole (1wk AmBd/Flu). A sensitivity analysis was conducted on key variables. RESULTS: The highest total treatment costs are in the 2-week AmBd/5FC arm followed by the 2-week oral regimen, the 1-week AmBd/5FC, then standard of care with the lowest cost in the 1-week AmBd/Flu arm. Compared to the lowest cost option the 1-week flucytosine course is most cost-effective at USD119/QALY. The cost impact analysis shows that the 1-week flucytosine course has an incremental cost of just over USD293 per patient per year compared to what is currently spent on standard of care. Sensitivity analyses suggest that the model is most sensitive to life expectancy and hospital costs, particularly infusion costs and length of stay. CONCLUSIONS: The addition of flucytosine as induction therapy for the treatment of cryptococcal meningitis in patients infected with HIV is cost-effective when it is used as a 1-week AmBd/5FC regimen. Savings could be achieved with early discharge of patients as well as a reduction in the price of flucytosine.
BACKGROUND:Cryptococcal meningitis in HIV-infectedpatients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin B. Recent evidence has shown that the synergistic use of flucytosine improves efficacy and reduces toxicity, however affordability and availability has hampered access to flucytosine in many countries. This study investigated the evidence and cost implications of introducing flucytosine as induction therapy for cryptococcal meningitis in HIV-infected adults in South Africa. METHODS: A decision analytic cost-effectiveness and cost impact model was developed based on survival estimates from the ACTA trial and local costs for flucytosine as induction therapy in HIV-infected adults with cryptococcal meningitis in a public sector setting in South Africa. The model considered five treatment arms: (a) standard of care; 2-week course amphotericin B/fluconazole (2wk AmBd/Flu), (b) 2-week course amphotericin B/flucytosine (2wk AmBd/5FC), (c) short course; 1-week course amphotericin B/flucytosine (1wk AmBd/5FC) (d) oral course; 2-week oral fluconazole/flucytosine (oral) and e) 1-week course amphotericin B/fluconazole (1wk AmBd/Flu). A sensitivity analysis was conducted on key variables. RESULTS: The highest total treatment costs are in the 2-week AmBd/5FC arm followed by the 2-week oral regimen, the 1-week AmBd/5FC, then standard of care with the lowest cost in the 1-week AmBd/Flu arm. Compared to the lowest cost option the 1-week flucytosine course is most cost-effective at USD119/QALY. The cost impact analysis shows that the 1-week flucytosine course has an incremental cost of just over USD293 per patient per year compared to what is currently spent on standard of care. Sensitivity analyses suggest that the model is most sensitive to life expectancy and hospital costs, particularly infusion costs and length of stay. CONCLUSIONS: The addition of flucytosine as induction therapy for the treatment of cryptococcal meningitis in patientsinfected with HIV is cost-effective when it is used as a 1-week AmBd/5FC regimen. Savings could be achieved with early discharge of patients as well as a reduction in the price of flucytosine.
Entities:
Keywords:
5-flucytosine; Cost impact; Cost-effective; Cryptococcal meningitis; HIV
Authors: Radha Rajasingham; Rachel M Smith; Benjamin J Park; Joseph N Jarvis; Nelesh P Govender; Tom M Chiller; David W Denning; Angela Loyse; David R Boulware Journal: Lancet Infect Dis Date: 2017-05-05 Impact factor: 25.071
Authors: Leigh F Johnson; Olivia Keiser; Matthew P Fox; Frank Tanser; Morna Cornell; Chris J Hoffmann; Hans Prozesky; Andrew Boulle; Mary-Ann Davies Journal: AIDS Date: 2016-10-23 Impact factor: 4.177
Authors: Síle F Molloy; Cecilia Kanyama; Robert S Heyderman; Angela Loyse; Charles Kouanfack; Duncan Chanda; Sayoki Mfinanga; Elvis Temfack; Shabir Lakhi; Sokoine Lesikari; Adrienne K Chan; Neil Stone; Newton Kalata; Natasha Karunaharan; Kate Gaskell; Mary Peirse; Jayne Ellis; Chimwemwe Chawinga; Sandrine Lontsi; Jean-Gilbert Ndong; Philip Bright; Duncan Lupiya; Tao Chen; John Bradley; Jack Adams; Charles van der Horst; Joep J van Oosterhout; Victor Sini; Yacouba N Mapoure; Peter Mwaba; Tihana Bicanic; David G Lalloo; Duolao Wang; Mina C Hosseinipour; Olivier Lortholary; Shabbar Jaffar; Thomas S Harrison Journal: N Engl J Med Date: 2018-03-15 Impact factor: 91.245
Authors: Tao Chen; Lawrence Mwenge; Shabir Lakhi; Duncan Chanda; Peter Mwaba; Síle F Molloy; Adrian Gheorghe; Ulla K Griffiths; Robert S Heyderman; Cecilia Kanyama; Charles Kouanfack; Sayoki Mfinanga; Adrienne K Chan; Elvis Temfack; Sokoine Kivuyo; Mina C Hosseinipour; Olivier Lortholary; Angela Loyse; Shabbar Jaffar; Thomas S Harrison; Louis W Niessen Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Angela Loyse; Jessica Burry; Jennifer Cohn; Nathan Ford; Tom Chiller; Isabela Ribeiro; Sinata Koulla-Shiro; Janneth Mghamba; Angela Ramadhani; Rose Nyirenda; Sani H Aliyu; Douglas Wilson; Thuy Le; Rita Oladele; Sokoine Lesikari; Conrad Muzoora; Newton Kalata; Elvis Temfack; Yacouba Mapoure; Victor Sini; Duncan Chanda; Meshack Shimwela; Shabir Lakhi; Jonathon Ngoma; Lilian Gondwe-Chunda; Chase Perfect; Amir Shroufi; Isabelle Andrieux-Meyer; Adrienne Chan; Charlotte Schutz; Mina Hosseinipour; Charles Van der Horst; Jeffrey D Klausner; David R Boulware; Robert Heyderman; David Lalloo; Jeremy Day; Joseph N Jarvis; Marcio Rodrigues; Shabbar Jaffar; David Denning; Chantal Migone; Megan Doherty; Olivier Lortholary; Françoise Dromer; Muirgen Stack; Síle F Molloy; Tihana Bicanic; Joep van Oosterhout; Peter Mwaba; Cecilia Kanyama; Charles Kouanfack; Sayoki Mfinanga; Nelesh Govender; Thomas S Harrison Journal: Lancet Infect Dis Date: 2018-10-18 Impact factor: 25.071
Authors: Mark W Tenforde; Adrienne E Shapiro; Benjamin Rouse; Joseph N Jarvis; Tianjing Li; Ingrid Eshun-Wilson; Nathan Ford Journal: Cochrane Database Syst Rev Date: 2018-07-25
Authors: Sally H Mohamed; Tinashe K Nyazika; Kenneth Ssebambulidde; Michail S Lionakis; David B Meya; Rebecca A Drummond Journal: Front Immunol Date: 2022-04-01 Impact factor: 8.786